TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > TGA Issues guidance for sponsors with lapsing Conformity Assessment Certificates

TGA Issues guidance for sponsors with lapsing Conformity Assessment Certificates

 Conformity Assessment Certificates

Author: Luis Jimenez

On 13 October 2020, the TGA specified that it will take a broader view in the case that companies suffer a lapse on renewing their Conformity Assessment Documents in response to the shortage on notified bodies ready to perform MDR and IVDR certifications, the travel bans preventing on-site audits and the current Covid-19 pandemic.

The guidance stipulates that:

“Where a Conformity Assessment Documents (CAD) has lapsed (that is, has expired solely because of passage of time and not because of regulatory action), this will not result in automatic cancellation of a device entry in the ARTG. The TGA will consider, in deciding whether suspension or cancellation of a device entry is warranted, whether the sponsor has taken reasonable steps to mitigate the problem.”

Although the guidance does not specify exactly for how long the TGA may extend the ARTG lifetime, it provides the criteria under which extensions will be evaluated.

Who does this impact?

Conformity Assessment Document refers to the underlying evidence of an overseas regulator approval that the manufacturer has used for an Australian ARTG. This usually refers to a CE Mark or in the case of MDSAP-holding companies US approvals, Health Canada Approval and/or Japanese approval. If you are having challenges renewing your Conformity Assessment Documents, you need to reach out to the TGA to ensure they are aware of the situation.

It also applies to companies that were required to have a review by the TGA prior to approval. This includes all products registered in Australia that are class III, active implantable medical devices (AIMDs) and all products containing tissues, cells or substances of microbial or recombinant origin. Again, in order to prevent interruption of supply communication with the TGA about this is critical.

What about novel technologies or new market entrants?

Unfortunately, this guidance or associated exemption does not apply to companies that have been negatively affected by delays in getting their first conformity assessment certificate due to the delays on MDR implementation of the Covid-19 Pandemic. In other words, it only applies to companies that already have had a conformity assessment.

What about companies that have not been able to secure the proper MDR CE Marks and whose MDD CE Mark holding has expired?

While working closely with the TGA and not having any regulatory action associated with your products is the key, this guidance provides a possible pathway to allow companies who have an expired MDD certificate and have been actively trying to get in the queue for MDR or a renewal under MDD eligible for continued market access in Australia.

Evaluation Criteria for the TGA not cancelling the Conformity Assessment Certificates

The TGA’s guidance specified that it will take into account the following six (6) factors in determining if the manufacturer will be able to continue to supply products to Australia in the case of a lapse in Conformity Assessments.

  1. The steps which the sponsor has taken to mitigate the situation
  2. Timeliness of the sponsor’s actions
  3. The extent to which the sponsor has kept the TGA informed
  4. Whether the sponsor in the absence of a CAD has provided information to the TGA to substantiate that the devices have had the conformity assessment procedures, or requirements comparable to the conformity assessment procedures, to the satisfaction of an overseas regulator, applied to them
  5. the presence or absence of other reasons for the lack of a current CAD

The TGA urges sponsors and manufacturers to reach out to the TGA promptly:

  • if their Conformity Assessment Documents (CAD)s are pending expiry and there may be issues with obtaining extensions or new CADs, outlining what steps they are taking to address the problem;
  • in the case of a TGA issues Conformity Assessment Certificate (CAC): submitting an extension application to the TGA at least six months prior to the expiry of the current CAC; or
  • if their CADs have already lapsed, the reasons for the lapse, and what action they are taking to address this issue.

Sponsors (or if relevant, manufacturers) should notify the Devices Post Market Reforms and Reviews Section of the above matters, together with relevant supporting documents, at postmarketdevices@health.gov.au

“The TGA will take failure to inform it promptly of the above matters into account when deciding whether device entries should be suspended or cancelled.”

As the compounding challenges of MDR and IVDR transitions, shortages of reviewers/notified bodies, travel bans and the covid-19 pandemic continue to unfold; open and transparent communication with regulators is more critical than ever.

If you have questions about how to engage with regulatory bodies such as TGA, please reach out to us to explore how we can assist in navigating both the regulatory changes, but also the required communications with regulatory agencies.

References

The TGA’s approach to delays in medical device conformity assessment recertification
https://www.tga.gov.au/resource/tgas-approach-delays-medical-device-conformity-assessment-recertification

Therapeutic Goods (Medical Devices) Regulations 2002. Conformity Assessment Procedures (Compilation Date: 25 August 2020)
https://www.legislation.gov.au/Details/F2020C00822

Contact us
Related posts
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
26th February 2022
Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
24th February 2022
Recent Blogs
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
  • How Advanced Therapeutic Mergers & Acquisitions Impact Negotiations and Integration
    26th February 2022
  • Planning for Post-Emergency Use Authorization (EUA) for Medical Devices and IVDs
    24th February 2022
Recent News
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
  • PharmaLex extends reach to Japan, East Asia and Southeast Asia with Ascent Development Services merger
    8th February 2022
  • Virtual Audits: To be, or not to be, that is the question
    26th January 2022
Upcoming Events

September 28 - May 29th, 2022

NLS DAYS 2022

Visit us at booth X51

Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
16h

Listen to our #podcast:
➡  Navigating a complex regulatory environment with medical device software

#SaMD #Medicaldevices #regulatoryaffairs

https://lnkd.in/eqKbz89J

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Able to explain technical details so non-experts can understand

    US based small / virtual company
    Partner
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.





    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for